Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2016-01-28 Interim / Quarterly Rep…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Quarterly Share Update - December 2015 9 pages 153.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Shareholder Update – December 2015' and contains detailed discussion of business progress, drug development pipeline, clinical trial updates, collaborations, and financial metrics for the quarter ended 31 December 2015. It includes substantive financial data such as income statements and segment results for the quarter and six months ended 31 December 2015 and 2014. The content is comprehensive and covers a period shorter than a full fiscal year, consistent with a quarterly report. There is no indication that this is merely an announcement or a brief summary; rather, it contains detailed operational and financial information. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q2 2016
2016-01-28 English
Updated Investor Presentation 25 pages 727.8KB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation' and contains detailed information about the company's business focus, drug development pipeline, management team, financial strength, partnerships, clinical trial data, and market opportunities. It includes forward-looking statements and strategic information aimed at investors. There are no full financial statements or regulatory filings typical of annual or quarterly reports. The content is consistent with a presentation designed to inform investors about the company's strategy, products, and market position rather than a formal report or regulatory filing. Therefore, the document fits the category of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2016-01-11 English
Appendix 3B - exercise of employee options 12 pages 136.1KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules related to securities issuance and quotation. It details the class and number of securities issued, exercise prices, issue dates, and other information relevant to a new securities issue. The document is a formal announcement to the ASX regarding the issuance and quotation of additional securities by Pharmaxis Ltd. It does not contain financial statements, management discussion, or audit information. It is not a report but an official announcement of a capital raising event and securities issuance. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains detailed information about the securities issued, consistent with a capital/financing update filing.
2016-01-11 English
Bronchitol Paediatric CF Trial Reports Postive Results 4 pages 145.8KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 16 December 2015 from Pharmaxis Ltd announcing positive results from a Phase II clinical trial of Bronchitol in pediatric cystic fibrosis patients. It details the trial design, endpoints, results, safety profile, and future plans for regulatory submission. The content is focused on clinical trial outcomes and product development updates rather than financial results, management changes, or regulatory filings. It is not an earnings release, annual report, or any form of regulatory filing. The document is a press release announcing clinical trial results, which fits best under the category of a general regulatory announcement or miscellaneous filing. Given the absence of financial statements or detailed financial data, and the nature of the announcement, the most appropriate classification is Regulatory Filings (RNS).
2015-12-15 English
Investor presentation 18 pages 583.1KB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation' and contains detailed information about the company's business focus, drug development pipeline, partnerships, financials including income statements and balance sheets, and strategic outlook. It includes forward-looking statements, product portfolio, collaborations, market opportunities, and financial data for fiscal years and quarters. The content is typical of a presentation aimed at investors to provide a comprehensive overview of the company's operations, strategy, and financial position. There is no indication that this is a formal regulatory filing like an annual report (10-K) or interim report (IR), nor is it a transcript, audit report, or other specific filing type. The length (15,000 characters) and detailed content support classification as an Investor Presentation rather than a brief announcement or report publication notice.
2015-11-24 English
Results of Meeting 2 pages 90.5KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is dated 20 November 2015 and is addressed to the Australian Securities Exchange. It reports the outcomes of resolutions from the Annual General Meeting (AGM) of Pharmaxis Ltd held on 19 November 2015. The content includes detailed voting results for various resolutions such as approval of the remuneration report, reappointment of a director, grant of performance rights, renewal of takeover provisions, and amendments to the constitution. The document is focused on the official results of shareholder votes at the AGM, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 6705 characters, which is sufficient to contain detailed voting results rather than just an announcement of the meeting or a brief summary. Therefore, the correct classification is DVA with high confidence.
2015-11-19 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.